Mystery Cake Ruins Party For EpiPen TV Ad
This article was originally published in The Pink Sheet Daily
Mylan direct-to-consumer ad misleadingly suggested that as long as allergy sufferers have the product with them, they don’t need to do anything else to avoid anaphylactic shock, FDA says.
You may also be interested in...
SOBi’s oral mucositis treatment was studied in controlled trials that used patient-reported outcome measures, but their content validity has not been established, FDA’s Office of Prescription Drug Promotion says.
In its first investor meeting in four years, Mylan lays out plans to barge over the generics industry’s post-2013 so-called ‘reverse patent cliff’ by focusing on high-barrier-to-entry products – including generic Advair – and portfolio and geographic diversification.